Updated results of a phase 1b study of regorafenib (REG) 80 mg/day or 120 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).

被引：15

作者：

El-Khoueiry, Anthony B.

Kim, Richard D.

Harris, William Proctor

Sung, Max W.

Waldschmidt, Dirk

Cabrera, Roniel

Garosi, Vittorio Luigi

Zebger-Gong, Hong

Brennan, Barbara J.

Wang, Ying A.

Mueller, Udo

Ishida, Tatiane Cristine

Galle, Peter R.

机构：

[1] Univ Southern Calif, Los Angeles, CA 90007 USA

[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[3] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA

[4] Tisch Canc Inst Mt Sinai, New York, NY USA

[5] Univ Hosp Cologne, Cologne, Germany

[6] Univ Florida, Gainesville, FL USA

[7] Bayer SpA, Milan, Italy

[8] Bayer AG, Berlin, Germany

[9] Bayer HealthCare Pharmaceut, Whippany, NJ USA

[10] Bayer HealthCare Pharmaceut, Cambridge, MA USA

[11] ClinStat GmbH, Cologne, Germany

[12] Univ Med Ctr Mainz, Mainz, Germany

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.4078

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4078

引用

页数：2